EPIC 2025 Outdid Itself with Record-High 1,200 Applications
HONG KONG SAR - Media OutReach Newswire - 17 July 2025 - EPIC 2025, organised by Hong Kong Science and Technology Parks Corporation (HKSTP), has reached new heights with the 9th edition saw an influx of global applications hitting close to 1,200, entering from more than 70 economies, setting a record for the I&T arena gaining global recognition, and regional representation for the development of I&T ecosystems.
EPIC 2025 received 1,200 applications from 70+ economies.
With the application period open from March to June, the response to participating in one of Asia's largest innovation arenas has been taken by storm. Where global startups with solutions in Digital Health Tech, FinTech, and Green Tech will be seen at 60-second pitches to get through to an unprecedented US$100M targeted investment funding and US$240,000 cash prizes, backed by 20 global financial and corporate partners that manage collectively of an AUM close to US$100B and operate across Asia, Europe and North America.
Monetary payoff aside, business matching and investment opportunities, as well as an extensive experience will be made available throughout EPIC Week––putting innovative solutions on display for potential investors and corporate decision makers with Tech Spotlight, and pulling a glimpse into the vast opportunities of the cities with Greater Bay Area Exploration guided tour––the series of highlights entailing complimentary flight and accommodation sponsored (* T&C applies) to contestants overseas, are set to enable mid- to late-stage startups to grow from indigenous names to international labels.
'First time ever that we're met with over a thousand applications, it's a feat right off the bat––we're expecting to see more aspiring tech gurus and their auspicious ideas rise to this year's shifts,' said Albert Wong, CEO of HKSTP.
Currently in the works, multiple regional pitching sessions will be held July to August, for the best and brightest in US, Europe, APAC and Hong Kong, to show and tell a story of their visions, where only the top 100 will be making it to the next round into the finals, taking place in November at Kai Tak Cruise Terminal, Hong Kong's former international airport furbished to be a runway for an expedition in tech.
Please visit https://epic.hkstp.org for more details.Hashtag: #HKSTP
The issuer is solely responsible for the content of this announcement.
HKSTP
Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.
Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.
Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.
Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.
More information about HKSTP is available at www.hkstp.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
EU Readies €100 Billion No-Deal Plan to Match US 30% Tariff
(Bloomberg) -- The European Union plans to quickly hit the US with 30% tariffs on some €100 billion ($117 billion) worth of goods in the event of no deal and if US President Donald Trump carries through with his threat to impose that rate on most of the bloc's exports after Aug. 1. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US Why the Federal Reserve's Building Renovation Costs $2.5 Billion Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Milan Corruption Probe Casts Shadow Over Property Boom How San Jose's Mayor Is Working to Build an AI Capital As a part of a first wave of countermeasures, the EU would combine an already approved list of tariffs on €21 billion of US goods and a previously proposed list on an additional €72 billion of American products into one package, a European Commission spokesman said on Wednesday. The US exports, which include industrial goods such as Boeing Co. aircraft, US-made cars and bourbon whiskey, would face a levy that matches Trump's 30% threat, according to people familiar with the matter. The threatened retaliation from Brussels would hit about one-third of American exports to the EU, based on the €335 billion worth of US goods shipped to the bloc last year. The tariffs would be prepared to come into force next month but only if there is no deal and the US implements its levies after the August deadline, said the people who spoke on condition of anonymity to discuss private deliberations. The euro extended a fall after the report, down 0.3% at $1.1723, leading losses among major currencies. German bonds trimmed an earlier decline. The plans come as EU member states, including Germany, have hardened their positions in response to the US stiffening its negotiating stance. Berlin would be willing to even support the activation of the EU's anti-coercion instrument, or ACI, in a no-deal scenario, a government official said on condition of anonymity. This tool would come into play only if a deal fails to materialize. Trump announced two tariff deals on Tuesday — one with the Philippines and another with Japan, and both featured across-the-board duties on their imports that were lower than initially threatened. Also noteworthy was the 15% US levy on Japanese autos that was lower than the current 25% rate on major car exporters including the EU. European leaders are in Tokyo and Beijing this week for talks with some of the the bloc's biggest trading partners in Asia. US Treasury Secretary Scott Bessent, speaking with Bloomberg Television on Wednesday, said the EU hasn't yet brought anything as innovative as the Japanese offer. 'Talks are going better than they had been,' he said in the interview. 'I think that we are making good progress with the EU, but as I've said before, the EU has a collective action problem with 27 countries.' Explainer: All About the EU's Trade Weapon of Last Resort The EU's most potent trade tool is the ACI, and a growing number of member states is pushing for its use if a deal isn't reached. The instrument is primarily designed as a deterrent and is currently not on the table, with its activation requiring a qualified majority of member states to support the move. The ACI would enable the EU to launch a broad range of retaliatory actions, including new taxes on US tech giants, targeted curbs on US investments, and limiting access to the EU market. 'We are now approaching the decisive phase in the tariff dispute with the USA — we need a fair, reliable agreement with low tariffs,' German Chancellor Friedrich Merz told reporters in Berlin on Tuesday after a meeting with his Czech counterpart Petr Fiala. 'Without such an agreement, we risk economic uncertainty at a time when we actually need exactly the opposite.' The Commission, the EU's executive arm, is discussing the instrument with member states, the people said. While some capitals having been pushing to use the tool, most want to wait to see how the situation develops beyond Aug. 1 before progressing discussions further to try to achieve the required majority, they added. The overwhelming preference is to keep negotiations with Washington on track in a bid for an outcome to the impasse ahead of next month's deadline. EU and US negotiators are scheduled to continue talks on Wednesday. The US is now seen to want a near-universal tariff on EU goods higher than 10%, with increasingly fewer exemptions limited to aviation, some medical devices and generic medicines, several spirits, and a specific set of manufacturing equipment that the US needs, Bloomberg previously reported. The two sides have also discussed a potential ceiling for some sectors, as well as quotas for steel and aluminum and a way to ring-fence supply chains from sources that oversupply the metals. Any agreement would need Trump's sign off – and his position isn't clear. The US president wrote to the EU earlier in the month, warning of a 30% tariff on most of its exports from Aug. 1. Alongside a universal levy, Trump has hit cars and auto parts with a 25% customs tax, and steel and aluminum with double that. He's also threatened to target pharmaceuticals and semiconductors with new duties as early as next month, and recently announced a 50% duty on copper. Hoped-For Extension Before Trump's letter, the EU had been hopeful it was edging toward an initial framework that would allow detailed discussions to continue on the basis of a universal rate of 10% on many of the bloc's exports. While most capitals and officials accept that any agreement would be asymmetrical in favor of the US and see the EU facing higher than 10% rates, the bloc has been seeking wider exemptions than the US is offering, as well as looking to shield the bloc from future sectoral tariffs. The EU's €100 billion list would cover its response to Trump's universal duties as well as his tariffs on metals and cars. The level of pain that member states are prepared to accept varies, and some are open to landing on a higher 15% levy if enough exemptions are secured and the scope of the duty was clear, the people said. In addition to the tariffs on goods, the bloc's executive arm is also working on measures that could see export controls as well as restrictions on some services and public procurement contracts introduced in future, they said. --With assistance from Greg Ritchie and Annmarie Hordern. (Adds detail on US exports in fourth paragraph, Bessent comments in 11th) Elon Musk's Empire Is Creaking Under the Strain of Elon Musk Burning Man Is Burning Through Cash A Rebel Army Is Building a Rare-Earth Empire on China's Border Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All ©2025 Bloomberg L.P. Sign in to access your portfolio
Bloomberg
13 minutes ago
- Bloomberg
Uber Tests Option in the US to Match Female Riders and Drivers
Uber Technologies Inc. is piloting a new ride type in the US that will match female riders and drivers, expanding access to a safety feature it already offers in some international markets. The service will launch in Los Angeles, San Francisco and Detroit over the next few weeks, the company said in a statement Wednesday. Riders will see a new on-demand ride option called 'Women Drivers' alongside the existing UberX, Comfort, UberXL and Black offerings. Customers can reserve such a trip in advance, or set their preference in the app settings to increase the likelihood of being matched with a woman driver.
Yahoo
36 minutes ago
- Yahoo
Respiree Closes US$11.6M Series A Financing Round Led by We Venture Capital and ClavystBio
HOUSTON and SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, announced the successful closing of a US$11.6 million Series A financing round led by We Venture Capital and ClavystBio. The round also had participation from Adaptive Capital Partners, conversion of note securities from Mayo Clinic's Mayo Foundation for Medical Research and from existing investors including Greenwillow Capital Management, Seeds Capital, and she1K angel investment. Proceeds will support expansion of Respiree's commercial team and U.S. presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Respiree, with Founder and Chief Executive Officer Dr. Gurpreet Singh at Center 'The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,' said Dr. Gurpreet Singh, Founder and CEO of Respiree. 'What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality. We're now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up.' Respiree's innovative, augmented-AI platform seeks to support quicker, efficient and precise decision making in various healthcare settings by automating patient monitoring, care pathway management and clinical insight delivery. One of its flagship AI models developed during the Mayo Clinic Platform_Accelerate program, where Respiree graduated from, can help healthcare professionals detect patient deterioration earlier – including rapid response calls in general wards and unplanned ICU transfers. Published as a pre-print in The Lancet, this flagship AI model significantly reduced false alarms while maintaining strong sensitivity — outperforming the positive predictive value (PPV) of EPIC's deterioration index by a factor of six (54.9% vs 8%). Respiree is currently in the process of seeking clearance from the US Food and Drug Administration (FDA) for its flagship AI model. The goal is to integrate the model into its platform, 1Bio™, which already incorporates data from electronic health records (EHRs), mobile questionnaires, third party devices and Respiree's proprietary, U.S.-patented, FDA-cleared sensors to provide longitudinal insights into disease trajectories. 'We are very proud to welcome Respiree to the We VC portfolio,' said Louise Warme, Head of We Venture Capital. 'Respiree stands out in the market by providing a patient monitoring AI/ML + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration. Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution-focused team.' 'ClavystBio's investment in Respiree is central to our strategy of helping companies scale globally from and through Singapore. Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights. This further underscores our commitment to accelerating medtech innovations aimed at improving patient outcomes across care settings,' said Anselm Tan, Digital Health & MedTech Lead, ClavystBio. Respiree's current solutions include: Scalable AI modules designed to be device-agnostic, platform independent and EHR-compatible, with increased precision to identify patient deterioration across patient touchpoints with low false alarms Pathway-management modules designed to automate delivery of standardized care pathways and requirements for nurses and patients to execute Centralized, EHR-agnostic platform connected to a broad range of EHR environments and medical device systems, consolidating continuous real-time analytics and data from multiple sources Connected wearables with configurable acquisition settings for a range of use-cases, capable of capturing a broad range of cardio-respiratory measures 'Respiree has achieved much since Greenwillow Capital Management first invested in February 2022 and continued to support the Company in the convertible notes last year. We are incredibly encouraged by the commercialization of Respiree's products and services in tier-one markets and look forward to being part of Respiree's growth as it continues to transform patient care on a global scale. We very much welcome the new investors We VC, ClavystBio and Adaptive Capital and look forward to working together in Respiree's forward journey,' said Dr. Wong Mun Yew, Managing Partner of Oriza Greenwillow Technology Fund. Founded in Singapore, Respiree is now executing its global strategy to expand into new markets worldwide. Respiree's solutions are currently available in the U.S., Australia, and across Asia-Pacific (APAC). The company recently announced a partnership with Roche Diagnostics to launch pilot programs across the APAC region. The company has also established key international partnerships with leading global healthcare providers to support its expansion across both acute and home healthcare settings. A portion of the Series A funds will be used to strengthen operations with existing channel partners and accelerate the development of new business relationships. Respiree plans to expand its offerings into newer international markets including the Gulf Cooperation Council and Thailand. About RespireeRespiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( About We Venture CapitalWe Venture Capital is a specialized fund, investing globally in diagnostics start-ups, as well as digital solutions and life science tools disrupting diagnostics. Launched 2023, We VC is focused on Series A investments, but also invest Seed and Series B. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare. About ClavystBio ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. ( About Greenwillow Capital Management The Oriza Greenwillow Technology Fund is a venture capital fund established jointly by Greenwillow Capital Management Pte Ltd, an MAS-licensed fund management company based in Singapore, and Oriza Holdings, an investment firm from China with assets under management exceeding RMB120 billion. The Fund invests in early-stage technology start-ups in Singapore and the fast-growing markets of Southeast Asia, with a primary focus on the smart cities and health-tech sectors. For more information, please visit Press ContactCammy DuongLifeSci Communicationscduong@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
